Quest Partners LLC Purchases 2,381 Shares of RxSight, Inc. (NASDAQ:RXST)

Quest Partners LLC boosted its stake in shares of RxSight, Inc. (NASDAQ:RXST) by 346.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 3,069 shares of the company’s stock after buying an additional 2,381 shares during the period. Quest Partners LLC’s holdings in RxSight were worth $152,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in RxSight by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 1,524,510 shares of the company’s stock valued at $78,634,000 after buying an additional 40,500 shares during the period. Driehaus Capital Management LLC raised its stake in shares of RxSight by 74.9% during the second quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company’s stock valued at $42,490,000 after acquiring an additional 302,367 shares in the last quarter. Baillie Gifford & Co. boosted its holdings in shares of RxSight by 17.0% in the third quarter. Baillie Gifford & Co. now owns 419,004 shares of the company’s stock valued at $20,711,000 after purchasing an additional 60,789 shares during the period. Marshall Wace LLP purchased a new stake in shares of RxSight in the second quarter valued at approximately $19,512,000. Finally, Victory Capital Management Inc. grew its stake in RxSight by 21.0% in the third quarter. Victory Capital Management Inc. now owns 259,864 shares of the company’s stock worth $12,845,000 after purchasing an additional 45,161 shares in the last quarter. 78.78% of the stock is currently owned by institutional investors.

RxSight Price Performance

Shares of RxSight stock opened at $46.40 on Friday. The business has a 50 day simple moving average of $48.85 and a two-hundred day simple moving average of $52.44. The stock has a market capitalization of $1.87 billion, a P/E ratio of -55.90 and a beta of 1.19. RxSight, Inc. has a 12 month low of $28.88 and a 12 month high of $66.54.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on RXST. Oppenheimer lowered their target price on RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th. Jefferies Financial Group assumed coverage on shares of RxSight in a research note on Tuesday, October 29th. They set a “buy” rating and a $72.00 price objective for the company. Wells Fargo & Company lowered their price objective on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Stifel Nicolaus cut their target price on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Finally, Needham & Company LLC restated a “buy” rating and issued a $66.00 target price on shares of RxSight in a research note on Friday, September 13th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $61.63.

Insider Activity at RxSight

In other RxSight news, Director Jesse Anderson Corley purchased 11,111 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were purchased at an average cost of $45.37 per share, for a total transaction of $504,106.07. Following the completion of the transaction, the director now owns 468,571 shares of the company’s stock, valued at $21,259,066.27. The trade was a 2.43 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Ilya Goldshleger sold 3,100 shares of the stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $52.67, for a total transaction of $163,277.00. Following the completion of the sale, the insider now owns 42,246 shares of the company’s stock, valued at approximately $2,225,096.82. The trade was a 6.84 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 62,702 shares of company stock valued at $3,059,197. 9.36% of the stock is owned by insiders.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.